[Clinical study on cinobufotalin in treating chronic hepatitis B virus carriers].
X T Xu
Index: Zhongguo Zhong Xi Yi Jie He Za Zhi 13(8) , 473-5, 453-4, (1993)
Full Text: HTML
Abstract
In a preliminary study, carriers of hepatitis B virus were treated with Cinobufotalin, a preparation from toad, for 1-3 course of treatment. Results indicated that negative conversion rate was markedly higher in the treated groups (21.09%, 38.89%, 63.64% and 50%) than that of control groups (2.1%, 10.87%, 33.33% and 7.7% P < 0.001). By the end of treatment, positive conversion rate of anti-HBs and anti-HBe were also markedly higher in the former (19.29% and 23.45%) than that in the latter (4.26% and 7.14% P < 0.001). During the follow-up of 3-6 months, the positive rate of HBeAg in treated group (50%) raised as compared with the control group (20% P = 0.08). The results indicated that Cinobufotalin had a significant effect in inhibiting the replication of HBV.
Related Compounds
Related Articles:
2014-09-26
[Biochem. Biophys. Res. Commun. 452(3) , 768-74, (2014)]
2015-08-01
[Tumour Biol. 36 , 5763-71, (2015)]
2012-12-01
[J Pharmacopuncture 15 , 52-65, (2015)]
2013-04-01
[J. Zool. (Lond.) 289 , 270-278, (2013)]
1996-12-01
[Zhongguo Zhong Xi Yi Jie He Za Zhi 16(12) , 738-40, (1996)]